| P50 | author | James Wilson | Q16947166 |
| P2093 | author name string | Hui Peng | |
| | Shu-Jen Chen | |
| | Peter Bell | |
| | Soumitra Roy | |
| | C Angelica Medina-Jaszek | |
| | Jenny A Greig | |
| | Rebecca L Grant | |
| | Anna P Tretiakova | |
| | Anne Mentzinger | |
| | Jason Ohlstein | |
| | Omua Ahonkhai | |
| P2860 | cites work | Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal Muscle. | Q54457954 |
| | New microRNAs from mouse and human | Q24540176 |
| | A mammalian microRNA expression atlas based on small RNA library sequencing | Q24644709 |
| | MicroRNA-restricted transgene expression in the retina | Q27332143 |
| | Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 |
| | A microRNA polycistron as a potential human oncogene | Q27860720 |
| | Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 |
| | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 |
| | Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza | Q30431225 |
| | Muscle-specific microRNA miR-206 promotes muscle differentiation | Q30441356 |
| | Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque | Q32157141 |
| | Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity | Q33490137 |
| | Broad protection against influenza infection by vectored immunoprophylaxis in mice | Q33649040 |
| | Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus | Q33809225 |
| | AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 |
| | Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer | Q34516810 |
| | Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells | Q34574858 |
| | Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 |
| | Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results | Q35496285 |
| | Antibody-based protection against HIV infection by vectored immunoprophylaxis | Q35658856 |
| | Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 |
| | Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 |
| | Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. | Q36085709 |
| | Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 |
| | Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 |
| | Application of mutated miR-206 target sites enables skeletal muscle-specific silencing of transgene expression of cardiotropic AAV9 vectors. | Q36883822 |
| | Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver | Q36940126 |
| | miRNAs get an early start on translational silencing | Q36965104 |
| | Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys | Q37295534 |
| | Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy | Q37364038 |
| | Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 | Q39610645 |
| | Stable knockdown of microRNA in vivo by lentiviral vectors | Q39910684 |
| | Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. | Q40777442 |
| | Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 |
| | Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver | Q41753510 |
| | Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer | Q41920883 |
| | Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. | Q41972673 |
| | Construction and analysis of compact muscle-specific promoters for AAV vectors | Q42437569 |
| | microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors | Q43703662 |
| | Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. | Q43727676 |
| | Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy | Q43801966 |
| | Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects | Q44136395 |
| | Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. | Q45225518 |
| | Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 |
| | Muscle as a target for supplementary factor IX gene transfer | Q45869069 |
| | Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer | Q45874902 |
| | Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. | Q45882349 |
| | An optimized protocol for detection of E. coli beta-galactosidase in lung tissue following gene transfer. | Q45884158 |
| | Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy | Q45884700 |
| | Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. | Q45887588 |
| | Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy | Q45888356 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e112268 | |
| P577 | publication date | 2014-11-13 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression | |
| P478 | volume | 9 | |